EUVIMEDEUVIMED entdecken
Crossref

Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats

Eri Harada, Kazumi Sugino, Akira Takahara

Biological and Pharmaceutical Bulletin · 2024

DOI: 10.1248/bpb.b24-00265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biological and Pharmaceutical Bulletin, 2024. Verfasst von Eri Harada und 2 weiteren Autor:innen. Beteiligte Einrichtung: EA Pharma Co., Ltd. (Formerly Ajinomoto Pharmaceuticals Co., Ltd.). Hauptthemen laut MEDLINE: Valsartan, Rats, Inbred Dahl, Dihydropyridines, Calcium Channel Blockers. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The current study aimed to investigate the anti-atrial fibrillatory (AF) effects of a combination of valsartan and a calcium channel blocker (cilnidipine or amlodipine) in Dahl salt-sensitive (Dahl S) rats. Seven-week-old male Dahl S rats were fed an 8% salt diet. Six weeks later, valsartan (60 mg/kg, Val group), cilnidipine + valsartan (10 + 60 mg/kg, CV group), amlodipine + valsartan (3 + 60 mg/kg, AV group), or vehicle was orally administered daily for 5 weeks. Echocardiography and atrial electrophysiological evaluations were performed on the last day of treatment. Blood pressure in each drug treatment group was lower than in the Vehicle group. The duration of AF induced by atrial burst stimulation was shorter in the Val group (3.2 ± 1.6 s) than in the Vehicle group (11.2 ± 6.0 s), which was further shortened in the CV and AV groups (1.1 ± 0.3 and 1.3 ± 0.3 s, respectively). Left ventricular ejection fraction and left ventricular fractional shortening were greater in the CV and AV groups than those in the Vehicle group. Urinary albumin excretion in the CV group was the lowest among the drug-treated groups. The results collectively suggest that the combination of a calcium channel blocker with valsartan could be useful in terms of its anti-AF action as well as for improving cardiac and renal functions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ValsartanRats, Inbred DahlDihydropyridinesCalcium Channel BlockersBlood PressureAnimalsMaleAtrial FibrillationDrug Therapy, CombinationKidneyRatsAmlodipineVentricular Function, LeftHeart Atria

Stichwörter der Autor:innen

N-type Ca2+ channelatrial fibrillationcardiac remodelingcilnidipinecombination therapyvalsartan

Substanzen

ValsartanDihydropyridinescilnidipineCalcium Channel BlockersAmlodipine

Autor:innen und Institutionen

  • EA Pharma Co., Ltd. (Formerly Ajinomoto Pharmaceuticals Co., Ltd.).
  • Ajinomoto Co., Inc.
  • Department of Pharmacology and Therapeutics, Faculty of Pharmaceutical Sciences, Toho University.

Zitieren

APA

Harada, E., Sugino, K., & Takahara, A. (2024). Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats. Biological and Pharmaceutical Bulletin. https://doi.org/10.1248/bpb.b24-00265

Vancouver

Harada E, Sugino K, Takahara A. Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats. Biological and Pharmaceutical Bulletin. 2024. doi:10.1248/bpb.b24-00265

BibTeX
@article{Harada2024,
  author = {Harada, Eri and Sugino, Kazumi and Takahara, Akira},
  title = {Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats},
  journal = {Biological and Pharmaceutical Bulletin},
  year = {2024},
  doi = {10.1248/bpb.b24-00265}
}
Kostenlos starten →